Peptides which react with antibody representing the prognostic marker for hiv disease progression
CA 2205077 A1 · Owner: Diapharm Limited · Inventors: Metlas, Radmila; Veljkovic, Veljko
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to peptide sequences which react with human antibodies whose titre in sera of individuals infected with Human Immunodeficiency Virus type 1 (HIV-1) correlates with Acquired Immune Deficiency Syndrome (AIDS) progression. Hence these, peptides are useful in preparing test kits for the prognostic evaluation of the disease progression as, well as for monitoring the effect of the antiviral therapy on HIV-1 infectivity and modulate immune network. These peptides are also useful in vaccines to prevent the development of AIDS. Monoclonal antibodies against the peptides from this invention may also be used as a therapeutic agent to prevent AIDS progression.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 21, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 21, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 21, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.